Use of Omadacycline as a Component of Mycobacterium Abscessus Eradication in an Adolescent With Cystic Fibrosis.

Autor: Tucker MK; The Children's Hospital at Saint Francis (MKT, LD, MC), Tulsa, OK.; Warren Clinic Pediatric Pulmonology, Tulsa CF Center (MKT, LD, MC) Tulsa, OK., Droemer L; The Children's Hospital at Saint Francis (MKT, LD, MC), Tulsa, OK.; Warren Clinic Pediatric Pulmonology, Tulsa CF Center (MKT, LD, MC) Tulsa, OK., Condren M; The Children's Hospital at Saint Francis (MKT, LD, MC), Tulsa, OK.; Warren Clinic Pediatric Pulmonology, Tulsa CF Center (MKT, LD, MC) Tulsa, OK.; Department of Pediatrics (MC), The University of Oklahoma School of Community Medicine, Oklahoma City, OK.; Children's Medical Center Dallas (MKT) Dallas, TX.
Jazyk: angličtina
Zdroj: The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG [J Pediatr Pharmacol Ther] 2023; Vol. 28 (2), pp. 172-176. Date of Electronic Publication: 2023 Apr 26.
DOI: 10.5863/1551-6776-28.2.172
Abstrakt: Lung damage caused by non-tuberculous mycobacteria (NTM) infections can be devastating to individuals that are predisposed to chronic respiratory colonization. Cystic fibrosis patients are at increased risk for diminished lung function and increased mortality from NTM pulmonary infections. Treatment regimens are often intense and prolonged. The case described in this report is of a 16-year-old male with cystic fibrosis infected with Mycobacterium abscessus who showed evidence of severe nodular pulmonary disease on chest computerized tomography. His intensive treatment phase was complicated by neutropenia and drug resistance, leading to the use of omadacycline. Because of rapid improvement clinically and on computed tomography, he was successfully treated with a modified, less intense continuation phase that included azithromycin, omadacycline, and inhaled amikacin. The patient also was switched from tezacaftor/ivacaftor to elexacaftor/tezacaftor/ivacaftor during the course of NTM treatment.
Competing Interests: Disclosures. The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. The authors had full access to all patient information in this report and take responsibility for the integrity and accuracy of the report
(Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org.)
Databáze: MEDLINE
Externí odkaz: